Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials)
Véronique Crutel(Servier (France)), Bruno Falissard(Inserm), Simon Kyaga(Karolinska Institutet), Mara Parellada(Hospital General Universitario Gregorio Marañón), Joaquín Fuentes(Policlínica Gipuzkoa), Guiomar Oliveira(Hospitais da Universidade de Coimbra), Denis Ravel(Neurochlore (France)), Antoine Rosier(Centre Hospitalier du Rouvray), Pierre‐François Pénélaud(Servier (France)), Cristina Albarrán Severo(Servier (France)), Amaia Hervás(Mútua Terrassa), Sylvie Gouttefangeas(Servier (France)), Marianne Bertrand(Center for Economic and Policy Research), Stéphane Marret(Inserm)
Cited by 38
Related Papers
Amoxicillin plus clavulanic acid versus appendicectomy for treatment of acute uncomplicated appendicitis: an open-label, non-inferiority, randomised controlled trial
|The Lancet|2011|674
Genetic and Functional Analyses of SHANK2 Mutations Suggest a Multiple Hit Model of Autism Spectrum Disorders
|PLoS Genetics|2012|443
Complicated grief after death of a relative in the intensive care unit
|European Respiratory Journal|2015|359
Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder
|Nature Neuroscience|2017|309
Sample size requirements for the internal validation of psychiatric scales
|International Journal of Methods in Psychiatric Research|2011|298